Division of Mental Health Services, Akershus University Hospital, Lørenskog, Norway.
Institute of Clincial Medicine, University of Oslo, Oslo, Norway.
Adm Policy Ment Health. 2020 Nov;47(6):911-919. doi: 10.1007/s10488-020-01018-1.
The paper describes the Antipsychotic Medication Management Fidelity Scale and its psychometric properties, including interrater reliability, frequency distribution, sensitivity to change and feasibility. Fidelity assessors conducted fidelity reviews four times over 18 months at eight sites receiving implementation support for evidence-based antipsychotic medication management. Data analyses shows good to fair interrater reliability, adequate sensitivity to change over time and good feasibility. At 18 months, item ratings varied from poor to full fidelity on most items. Use of the scale can assess fidelity to evidence-based guidelines for antipsychotic medication management and guide efforts to improve practice. Further research should improve and better calibrate some items, and improve the procedures for access to information.Trial registration: ClinicalTrials.gov Identifier: NCT03271242.
本文描述了抗精神病药物管理保真度量表及其心理测量学特性,包括评分者间信度、频率分布、对变化的敏感性和可行性。在接受基于证据的抗精神病药物管理实施支持的 8 个地点,保真度评估员在 18 个月内进行了 4 次保真度审查。数据分析显示,评分者间信度良好至中等,随时间变化的敏感性足够,可行性良好。在 18 个月时,大多数项目的条目评分从较差到完全保真度不等。该量表的使用可以评估抗精神病药物管理的循证指南的保真度,并指导改善实践的努力。进一步的研究应改进和更好地校准一些项目,并改进获取信息的程序。试验注册:ClinicalTrials.gov 标识符:NCT03271242。